Issue of Share Options/PDMR Shareholdings
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your DXRX notes
Belfast and London, 29 July 2024- Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces the issue of 1,494,051 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP") on 23 July 2024. These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.
Share Options were granted as to PDMRs follows:
| Name | Number of Share Options granted | Total no. of ordinary shares under option post grant | % of existing issued share capital | Effective Grant date |
|---|---|---|---|---|
| Ryan Keeling, CEO | 236,250 | 581,947 | 0.69% | 23 July 2024 |
| Nick Roberts, CFO | 168,750 | 327,622 | 0.39% | 23 July 2024 |
| Julie Browne, COO and PDMR | 76,631 | 245,678 | 0.29% | 23 July 2024 |
| Jordan Clark, CDO and PDMR | 74,502 | 190,242 | 0.22% | 23 July 2024 |
| Susanne Munksted, CPO and PDMR | 74,647 | 284,829 | 0.34% | 23 July 2024 |
| Jillian Beggs, CCO and PDMR | 72,844 | 129,548 | 0.15% | 23 July 2024 |
A further 790,927 Share Options were granted to a total of 53 other employees.
The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth during the Performance Period in Total Shareholder Return ("TSR"), the revenue Compound Annual Growth Rate ("CAGR") and recurring revenue. The average mid-market closing share price in the three days prior to the issue of the Share Options was £1.33. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.
Following this grant, the total number of share options outstanding in the Company is 4,711,454 representing approximately 5.56% of its current issued share capital of 84,720,076.
| a. | Name | Ryan Keeling |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Executive Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Options over new ordinary shares of 0.2 p each ISIN: GB00BJQTGV64 |
| b. | Nature of the transaction | Grant of share options |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| Exercise price of 0.2p per share | 236,250 | |
| f. | Place of the transaction | Outside a trading venue |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Nick Roberts |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Finance Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Options over new ordinary shares of 0.2 p each ISIN: GB00BJQTGV64 |
| b. | Nature of the transaction | Grant of share options |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| Exercise price of 0.2p per share | 168,750 | |
| f. | Place of the transaction | Outside a trading venue |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Julie Browne |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Operations Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Options over new ordinary shares of 0.2 p each ISIN: GB00BJQTGV64 |
| b. | Nature of the transaction | Grant of share options |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| Exercise price of 0.2p per share | 76,631 | |
| f. | Place of the transaction | Outside a trading venue |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Jordan Clark |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Data Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Options over new ordinary shares of 0.2 p each ISIN: GB00BJQTGV64 |
| b. | Nature of the transaction | Grant of share options |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| Exercise price of 0.2p per share | 74,502 | |
| f. | Place of the transaction | Outside a trading venue |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Susanne Munksted |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Precision Medicine Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Options over new ordinary shares of 0.2 p each ISIN: GB00BJQTGV64 |
| b. | Nature of the transaction | Grant of share options |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| Exercise price of 0.2p per share | 74,647 | |
| f. | Place of the transaction | Outside a trading venue |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Jillian Beggs |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Commercial Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Options over new ordinary shares of 0.2 p each ISIN: GB00BJQTGV64 |
| b. | Nature of the transaction | Grant of share options |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| Exercise price of 0.2p per share | 72,844 | |
| f. | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.